| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(4 years from now) | |
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(5 years from now) | |
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(4 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(4 years from now) | |
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
Tepmetko is owned by Emd Serono Inc.
Tepmetko contains Tepotinib Hydrochloride.
Tepmetko has a total of 8 drug patents out of which 0 drug patents have expired.
Tepmetko was authorised for market use on 03 February, 2021.
Tepmetko is available in tablet;oral dosage forms.
Tepmetko can be used as treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib, treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib.
Drug patent challenges can be filed against Tepmetko from 03 February, 2025.
The generics of Tepmetko are possible to be released after 19 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET;ORAL
TEPMETKO family patents
